New global consortium aims to transform antibiotic discovery to counter the growing AMR crisis
Philanthropic partners invest US$60 million to support collaborative research to accelerate the discovery of next-generation antibiotics
The Gates Foundation, Novo Nordisk Foundation, and Wellcome today awarded a total of US$60 million in new grant funding over the next three years to research teams around the world exploring novel approaches to antibiotic discovery to deal with the growing threat of antimicrobial resistance (AMR). The Gram-Negative Antibiotic Discovery Innovator (Gr-ADI) will function as a first-of-its-kind consortium where multiple funders and research teams openly share data and learnings and work collectively to accelerate the discovery of urgently needed antibiotics.
